Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTB323 in relapsing multiple sclerosis with breakthrough disease activity
2024-512714-18-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Nov 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of rapcabtagene autoleucel in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Safety and dose-limiting toxicities. Planned start Nov 2025; status: authorised.
02
Drugs
rapcabtagene autoleucel
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-512714-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512714-18-00.